Enhanced Sensitivity in Acute Myocardial Infarction Diagnosis Through Optimized Multiplex Biomarker Detection on a Paper-Based Microfluidic Platform with Individual Control Capabilities
Lizhe Chen,Sixuan Duan,Tianyu Cai,Dechang Xu,Yong Hu,Chuanyu Zhang,Eng Gee Lim,Xueyong Wei,Pengfei Song
DOI: https://doi.org/10.1016/j.snb.2024.136616
2025-01-01
Abstract:Acute myocardial infarction (AMI) is a severe condition with high mortality, requiring timely diagnosis, especially in low-resource settings where centralized testing is unavailable. Leveraging our previously developed, reliable, highly integrated on-chip rotary valving system on the microfluidic paper-based analytical device (mu PAD), we propose a novel multiplex paper-based microfluidics immunoassay platform for the onsite detection of key cardiac biomarkers-Myoglobin (Myo), cardiac troponin I (cTnI), and creatine kinase-MB (CKMB)-in artificial serum. It enhances assay performance through individually controlled assay conditions, facilitating rapid AMI diagnosis. Compared to existing paper-based multiplex microfluidic ELISA systems, our mu PAD uniquely enables the assay of each biomarker under separate, optimally controlled incubation conditions within a single test through the valving system, which leads to optimized signal-to-noise ratio (SNR) performance and introduces more flexibility in multiplex testing. The valving system in the mu PAD is driven by a single servo motor, which is controlled via a microcontroller and an interactive touchscreen. These components are integrated into a highly programmable, easy-to-assemble platform that offers fast, low-cost, and user-friendly operation. Utilizing our platform, autonomous ELISA assays were performed on Myo, cTnI, and CKMB for calibration, achieving limits of detection (LOD) of 1.43 ng/mL for Myo, 0.2 ng/mL for cTnI, and 0.735 ng/mL for CKMB. Subsequent spike-and-recovery experiments also confirmed the platform's accuracy and precision in obtaining the test results within 30 minutes and 20 mu L serum sample. These results highlight the platform's transformative potential for clinical AMI diagnosis and commercialization, providing a cost-effective and accessible solution for point-of-care testing in diverse settings.